| Autor: |
Raffaella Greco, Tobias Alexander, Nicoletta Del Papa, Fabian Müller, Riccardo Saccardi, Fermin Sanchez-Guijo, Georg Schett, Basil Sharrack, John A. Snowden, Karin Tarte, Francesco Onida, Isabel Sánchez-Ortega, Joachim Burman, Cristina Castilla Llorente, Ricard Cervera, Fabio Ciceri, Andrea Doria, Jörg Henes, James Lindsay, Andreas Mackensen, Paolo A. Muraro, Elena Ricart, Montserrat Rovira, Tsila Zuckerman, Ibrahim Yakoub-Agha, Dominique Farge |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
EClinicalMedicine, Vol 69, Iss , Pp 102476- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2589-5370 |
| DOI: |
10.1016/j.eclinm.2024.102476 |
| Popis: |
Summary: Autoimmune diseases (ADs) are characterized by loss of immune tolerance, high chronicity, with substantial morbidity and mortality, despite conventional immunosuppression (IS) or targeted disease modifying therapies (DMTs), which usually require repeated administration. Recently, novel cellular therapies (CT), including mesenchymal stromal cells (MSC), Chimeric Antigen Receptors T cells (CART) and regulatory T cells (Tregs), have been successfully adopted in ADs. An international expert panel of the European Society for Blood and Marrow Transplantation and the International Society for the Cell and Gene Therapy, reviewed all available evidence, based on the current literature and expert practices, on use of MSC, CART and Tregs, in AD patients with rheumatological, neurological, and gastroenterological indications. Expert-based consensus and recommendations for best practice and quality of patient care were developed to support clinicians, scientists, and their multidisciplinary teams, as well as patients and care providers and will be regularly updated. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
